Although research on the effects of β3-AR stimulation on the microbiota remains very limited, β3-AR agonist treatment has been shown to alter gut microbiota composition in several models of obesity and thermogenesis (Paz et al., 2022; Samanta et al., 2024). The gene discussed is ADRB3; the disease is obesity due to melanocortin 4 receptor deficiency.